Relmada Therapeutics 주식 (NASDAQ: RLMD)

Relmada Therapeutics (NASDAQ:RLMD) 주식

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Premarket Trading

Opinion

Trading Ideas

EPSN

RLMD

매일 많은 이야기와 논의가 내부자 매수에 대해 인터넷에 올라온다. 대부분은 기업 내부자들의 매수 및 매도 활동에 대한 연구가 책 표지의 소개글을 읽는 데 그치는 사람들에 의해 작성된 것처럼 보인다. 일부 내부자 매수는 중요하다. 반면, 일부는 도움이 거의 안된다.

시장을 일관되게 능가하는 내부자 거래를 찾는 방법 - 언더 더 레이더

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and lowers the price target from $58 to $36.

News

Price Target

Analyst Ratings

FIVN

Rosenblatt Maintains Buy on Five9, Lowers Price Target to $36

Piper Sandler analyst Adam Maeder upgrades Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) from Neutral to Overweight and raises the price target from $73 to $80.

Upgrades

Piper Sandler Upgrades Edwards Lifesciences to Overweight, Raises Price Target to $80

Needham analyst James Ricchiuti maintains Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) with a Buy and lowers the price target from $585 to $550.

Needham Maintains Buy on Teledyne Technologies, Lowers Price Target to $550

ConnectOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNOB#NASDAQ">CNOB</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.46 by 10.87 percent. This is a 24.39 percent increase over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $65.76 million which missed the analyst consensus estimate of $67.65 million by 2.80 percent. This is a 9.05 percent increase over sales of $60.30 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

CNOB

ConnectOne Bancorp Q1 Adj. EPS $0.51 Beats $0.46 Estimate, Sales $65.76M Miss $67.65M Estimate

A coalition of over 30 leading artificial intelligence researchers and ethicists has issued an urgent warning about OpenAI&#8216;s proposed corporate restructuring, expressing grave concerns that the changes could undermine <a href="https://www.benzinga.com/news/24/09/41038183/openais-restructure-from-non-profit-to-potential-150b-for-profit-sam-altman-could-get-equity">public oversight and the company&#8217;s original mission</a>.
What Happened: The group published an open letter on the &#8220;Not For Private Gain&#8221; website urging California and Delaware Attorney Generals to intervene in OpenAI&#8217;s plan to buy itself out from under its nonprofit&#8217;s control. 
The letter argues that this restructuring would eliminate crucial governance safeguards designed to prioritize public benefit over commercial interests.
&#8220;Removing nonprofit control over how AGI [Artificial general intelligence] is developed and governed would violate the special fiduciary duty owed to the nonprofit&#8217;s beneficiaries and pose a palpable and identifiable threat to OpenAI&#8217;s charitable purpose,&#8221; the signatories stated.
The expert coalition includes AI pioneer Geoffrey Hinton, notable former OpenAI researchers Steven Adler, Jacob Hilton, Daniel Kokotajlo, Gretchen Krueger, Girish Sastry, Scott Aaronson, Ryan Lowe, Nisan Stiennon, and Anish Tondwalkar. Harvard law professor Lawrence Lessig, UC Berkeley computer science professor Stuart Russell, and Hugging Face ethics scientist Margaret Mitchell also joined the effort.
"Our board has been very clear: our nonprofit will be strengthened, and any changes to our existing structure would be in service of ensuring the broader public can benefit from AI," an OpenAI spokesperson <a href="https://www.cnbc.com/2025/04/23/ex-openai-staffers-urge-california-delaware-not-to-allow-restructure.html">told</a> CNBC.
See Also: <a href="https://www.benzinga.com/news/legal/25/04/44941262/openai-once-tried-to-use-googles-search-technology-instead-of-microsoft-bing-due-to-quality-issues-was-rejected-now-sam-altmans-startup-says-itd-buy-chrome-if-forced-antitrust-sale-happens">OpenAI Eyes Chrome Takeover: Sam Altman Ready To Pounce If Google Forced To Sell The Web Browser, Executive Reveals</a>
Why It Matters: This intervention comes at a critical juncture <a href="https://www.benzinga.com/media/25/01/43374528/softbank-may-lead-openais-40-billion-funding-round-at-a-300-billion-valuation-despite-deepseek-disruption-report">as OpenAI must complete its restructuring</a> by year-end to secure the full $40 billion funding round led by SoftBank Group Corp. 
The company plans to <a href="https://www.benzinga.com/media/24/12/42709007/sam-altmans-openai-plans-major-revamp-corporate-structure">transform into a Delaware Public Benefit Corporation</a>, allowing it to attract conventional equity investments while its nonprofit arm focuses on charitable initiatives.
The AI experts&#8217; objections parallel ongoing litigation from OpenAI co-founder Elon Musk, whose xAI Corp now competes with OpenAI after raising $6 billion in funding. Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), which has invested nearly $14 billion in OpenAI, could also be significantly impacted by any <a href="https://www.benzinga.com/24/12/42712824/elon-musks-legal-battle-against-openais-for-profit-transition-joined-by-non-profit-encode">regulatory action affecting the restructuring</a>.
The dispute highlights growing tensions between OpenAI&#8217;s original mission to ensure artificial general intelligence &#8220;benefits all of humanity&#8221; and its commercial ambitions, raising fundamental questions about who should control and govern powerful AI technologies with potentially transformative global impacts. Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44828934/musk-could-not-tolerate-seeing-such-success-openai-says-he-abandoned-and-declared-them-doomed-then-tried-to-destroy-it-all" target="_blank" rel="noopener">&#8216;Musk</a><a href="https://www.benzinga.com/personal-finance/25/04/44828934/musk-could-not-tolerate-seeing-such-success-openai-says-he-abandoned-and-declared-them-doomed-then-tried-to-destroy-it-all"> Could Not Tolerate Seeing Such Success&#8217; — OpenAI Says He Abandoned And Declared Them &#8216;Doomed,&#8217; Then Tried to Destroy It All</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Legal

Tech

MSFT

Geoffrey Hinton, Ex-OpenAI Insiders, And Top AI Experts Sound Alarm On OpenAI's Restructuring: Warn It Could Strip Public Of Oversight, Betray AGI Mission

NOW: 10% &#x7C; <a href="https://www.benzinga.com//node/44973825">ServiceNow shares are trading higher after the company reported better-than-expected Q1 financial results.</a>
&nbsp;
TXN: 9% &#x7C; <a href="https://www.benzinga.com//node/44973870">Texas Instruments shares are trading higher after the company reported Q1 financial results and beat its EPS and sales estimates. Additionally, the company issued Q2 sales guidance above estimates.</a>
&nbsp;
LUV: -6% &#x7C; <a href="https://www.benzinga.com//node/44973774">Southwest Airlines shares are trading lower following Q1 earnings. The company said it is not reiterating its full year 2025 or 2026 EBIT guides and said amid macroeconomic uncertainty, it is 'difficult to forecast given recent and short-lived booking trends.'</a>

Movers

Market-Moving News for April 24th

Manhattan Bridge Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOAN#NASDAQ">LOAN</a>) reported quarterly earnings of $0.12 per share which met the analyst consensus estimate. This is a 7.69 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $2.27 million which beat the analyst consensus estimate of $1.41 million by 61.85 percent. This is a 11.62 percent decrease over sales of $2.57 million the same period last year.

LOAN

Manhattan Bridge Capital Q1 EPS $0.12, Inline, Sales $2.27M Beat $1.41M Estimate

Contracts

General

INVE

Identiv Announced A Business Development And Marketing Partnership With Tag-N-Trac, To Initially Focus On Developing And Commercializing Specialized IoT Solutions For Cold Chain Tracking Within The Pharmaceutical Industry Supply Chain

Guidance

Fiserv Affirms FY2025 Adj EPS Guidance of $10.10-$10.30 vs $10.22 Est

American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) is looking for Q2 Adj EPS of $0.50-$1.00 vs $0.99 analyst estimate..

American Airlines Group Sees Q2 Adj EPS $0.50-$1.00 vs $0.99 Est

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) with a Buy and maintains $11 price target.

Reiteration

SANA

HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $11 Price Target

FNWB

First Northwest Bancorp Q1 EPS $0.17 Beats $0.13 Estimate, Sales $17.94M Beat $16.45M Estimate

PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) raises FY2025 sales outlook from $320.00 million to $323.00 million vs $321.96 million estimate.

PRCT

PROCEPT BioRobotics Raises FY2025 Sales Guidance from $320.00M to $323.00M vs $321.96M Est

American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.65) by 9.23 percent. This is a 73.53 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $12.55 billion which missed the analyst consensus estimate of $12.60 billion by 0.42 percent. This is a 0.15 percent decrease over sales of $12.57 billion the same period last year.

American Airlines Group Q1 Adj. EPS $(0.59) Beats $(0.65) Estimate, Sales $12.55B Miss $12.60B Estimate

Rosenblatt analyst Catharine Trebnick maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Buy and lowers the price target from $40 to $28.

Rosenblatt Maintains Buy on RingCentral, Lowers Price Target to $28

2025 Adjusted EBITDA guidance improved: Raising full year shipments growth forecast range to between 3-4%, following the positive start to the year. Higher shipments growth expectations and favorable currency movements increase the Adjusted EBITDA guidance range to between $695-$720 million – based on prevailing currency rates (euro/dollar at 1.14 resulting in an expected 2025 average of 1.11 vs. 1.086 average for 2024). &nbsp;

AMBP

Ardagh Metal Packaging Raises 2025 Adjusted EBITDA Guidance To $695M–$720M (From $675M-695M) On Strong Shipments And Favorable Currency Trends

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) with a Buy and lowers the price target from $11.5 to $11.

IPHA

HC Wainwright & Co. Reiterates Buy on Innate Pharma, Lowers Price Target to $11

Fiserv Q1 Adj. EPS $2.14 Beats $2.07 Estimate, Sales $5.13B Beat $4.84B Estimate

We confirm our full-year 2025 earnings guidance range of $11.10 to $11.60 per diluted share, which includes the impact of year-to-date tax benefits of $0.10. As we approach the swimming pool season, we remain focused on strengthening our industry-leading position through disciplined execution, continued innovation of our customer-centric POOL360 digital ecosystem, growing our sales center network and a relentless commitment to helping our customers grow their businesses," said Arvan.

POOL

Pool Raises FY2025 GAAP EPS Guidance From $11.08-$11.58 To $11.10-$11.60 Vs $11.42 Estimate

Morgan Stanley analyst Betsy Graseck maintains Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) with a Underweight and lowers the price target from $585 to $450.

Morgan Stanley Maintains Underweight on Lennox Intl, Lowers Price Target to $450

Press Releases

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Health Care

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Comments

Relmada Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌